LifeMD, Inc.

Listed Company

LFMDCIK 0000948320NasdaqAcceleratedServices-Offices & Clinics Of Doctors Of MedicineDelawareFY ends Dec 31

Period

FY 2024

Revenue

$212.45M

Net Income

$-18.88M

Total Assets

$72.46M

Equity

$-5.49M

Shares Out

48.36M

Op. Cash Flow

$17.51M

LFMD$4.14−62.67% · past yearDBEQ Basic

Daily closing prices

Business

LifeMD, Inc. is a direct-to-patient telehealth and pharmacy company delivering virtual primary care, specialty health services, and prescription fulfillment through a vertically integrated platform. The company offers subscription-based virtual consultations, prescription medications, diagnostics, and wellness coaching across conditions including primary care, weight management, men's health, women's health, and behavioral health. LifeMD operates three consumer brands—LifeMD, Rex MD, and ShapiroMD—supported by an affiliated 50-state medical provider network, a wholly-owned commercial pharmacy, patient care center, and proprietary technology platform. Distribution occurs direct-to-patient via desktop and mobile applications, with expanding commercial and government insurance coverage.

Summary from 10-K filed 2026-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Total revenues, net	212	153	119	93	37
Total cost of revenues	24	19	19	18	9
Gross profit	188	134	100	75	28
Selling and marketing expenses	103	76	78	83	39
General and administrative expenses	73	52	47	40	45
Customer service expenses	10	8	5	3	716,325
Development costs	10	6	3	948,157	446,749
Other operating expenses	9	6	7	3	1
Total expenses	205	148	144	129	86
Operating loss	−16	−14	−43	−54	−58
Interest expense, net	−2	−3	−1	−3	−2
Loss on debt extinguishment	—	−325,198	63,400	−4	−914,862
Loss from operations before income taxes	−18	−17	−45	−61	−60
Income tax provision	−402,000	−428,000	−360,700	−7,700	−122,500
Net loss	−19	−18	−45	−61	−61
Net income attributable to non-controlling interest	153,000	3	514,632	−426,352	−2
Net loss attributable to LifeMD, Inc.	−19	−21	−46	−61	−59
Preferred stock dividends	−3	−3	−3	−871,476	—
Net loss attributable to LifeMD, Inc. common stockholders	−22	−24	−49	−62	−63
Basic loss per share attributable to LifeMD, Inc. common stockholders	−0.53	−0.7	−1.57	−2.29	−4.44
Diluted loss per share attributable to LifeMD, Inc. common stockholders	−0.53	−0.7	−1.57	−2.29	−4.44
Basic	41	34	31	27	14
Diluted	41	34	31	27	14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cash	35	33	4	41	9
Accounts receivable, net	8	5	3	980,055	997,757
Product deposit	41,000	486,000	127,000	204,000	817,000
Inventory, net	3	3	4	2	1
Other current assets	3	934,510	687,022	793,190	154,876
Total Current Assets	49	43	11	45	12
Equipment, net	1	476,303	476,441	233,805	—
Right of use assets	6	594,897	1	2	274,437
Capitalized software, net	14	12	9	3	375,983
Intangible assets, net	2	3	4	19,761	339,840
Total Non-current Assets	24	16	14	5	990,260
Total Assets	72	58	26	50	13
Accounts payable	16	11	10	9	—
Accrued expenses	21	14	12	12	—
Notes payable, net	—	327,597	3	63,400	779,132
Current operating lease liabilities	508,537	603,180	756,093	607,490	93,001
Current portion of long-term debt	8	—	—	—	—
Deferred revenue	14	9	6	1	—
Total Current Liabilities	60	35	31	23	14
Long-term debt, net	10	18	—	—	—
Noncurrent operating lease liabilities	6	73,849	574,136	1	192,322
Contingent consideration	100,000	131,250	443,750	100,000	100,000
Total Liabilities	77	53	33	24	14
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero shares issued and outstanding, liquidation value, $0 per share as of December 31, 2024 and 2023	—	—	5	4	4
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $25.55 per share as of December 31, 2024 and 2023	140	140	140	140	—
Common Stock, $0.01 par value; 100,000,000 shares authorized, 42,293,907 and 38,358,641 shares issued, 42,190,867 and 38,255,601 outstanding as of December 31, 2024 and 2023, respectively	422,939	383,586	315,528	307,045	234,337
Additional paid-in capital	231	218	179	165	78
Accumulated deficit	−236	−214	−191	−142	−80
Treasury stock, 103,040 shares, at cost, as of December 31, 2024 and 2023	−163,701	−163,701	−163,701	−163,701	−163,701
Total LifeMD, Inc. Stockholders (Deficit) Equity	−5	4	−11	23	−2
Non-controlling interest	1	2	−475,548	−1	−2
Total Stockholders (Deficit) Equity	−4	6	−12	22	−4
Total Liabilities, Mezzanine Equity and Stockholders (Deficit) Equity	72	58	26	50	13

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Amortization of debt discount	401,775	333,939	—	2	817,118
Amortization of capitalized software	8	5	3	512,887	62,153
Amortization of intangibles	982,000	971,000	927,000	342,310	335,612
Accretion of consideration payable	13,644	167,221	273,822	—	—
Depreciation of fixed assets	487,976	203,952	161,885	13,560	—
Write-down of inventory	675,669	537,685	103,417	57,481	—
Noncash operating lease expense	776,080	766,280	546,439	22,700	4,533
Stock issued for legal settlement	—	532,000	816,000	—	—
Stock compensation expense	12	12	14	12	19
Accounts receivable	−3	−2	−2	17,702	−816,756
Product deposit	445,087	−358,585	76,291	613,209	−666,765
Inventory	−713,095	405,746	−2	−409,823	−314,199
Other current assets	−2	−247,488	106,168	−638,314	95,595
Operating lease liabilities	−485,079	−808,368	−455,805	—	—
Deferred revenue	6	3	4	583,000	807,328
Accounts payable	5	978,062	1	−893,956	—
Accrued expenses	8	5	−1	10	—
Other operating activity	—	−579,319	−888,486	—	—
Net cash provided by operating activities	18	9	−23	−33	−12
Cash paid for capitalized software costs	−10	−8	−9	−3	−398,136
Purchase of equipment	−1	−203,814	−366,633	−247,365	—
Purchase of intangible assets	−3,798	−148,868	−4	−22,231	—
Net cash used in investing activities	−12	−9	−14	−3	−798,136
Proceeds from long-term debt, net	—	19	—	—	2
Cash proceeds from common stock issued to Medifast	—	10	—	493,481	2
Proceeds from notes payable	—	2	3	963,965	242,000
Sale of common stock under ATM, net	—	6	—	—	—
Repayment of notes payable, net of prepayment penalty	−327,597	−5	−168,750	−1	−2
Cash proceeds from exercise of options	120,312	94,500	90,400	670,750	302,400
Preferred stock dividends	−3	−3	−3	−871,476	—
Contingent consideration payments for ResumeBuild acquisition	−31,250	−312,500	−156,250	—	—
Net payments for membership interest in WorkSimpli	—	−305,625	12,150	—	—
Distributions to non-controlling interest	−773,888	−144,000	−144,000	−144,000	−157,223
Net cash (used in) provided by financing activities	−4	29	−528,200	69	21
Net increase in cash	2	29	−37	32	8
Cash paid during the period for interest	3	2	189,000	435,048	2
Cashless exercise of options	5,127	744	297	8,730	—
Cashless exercise of warrants	16,305	793	—	—	—
Stock issued for noncontingent consideration payments	642,000	3	—	—	—
Stock issued for debt conversion	—	1	—	—	—
Series B Preferred Stock conversion	—	5	—	—	—
Warrants issued for debt instruments	—	873,100	—	6	—
Right of use assets	7	155,168	89,595	2	274,437
Operating lease liabilities	7	155,168	94,168	2	285,323

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is LifeMD, Inc.'s CIK number?

LifeMD, Inc.'s SEC CIK number is 0000948320 (948320). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find LifeMD, Inc.'s SEC filings?

All of LifeMD, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did LifeMD, Inc. last report earnings?

LifeMD, Inc. (LFMD) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-021520). This is LifeMD, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is LifeMD, Inc.'s most recent earnings 8-K?

LifeMD, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001493152-26-021520. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View LifeMD, Inc.'s latest earnings 8-K →
Look up any company's CIK number →